Grail

Activist Icahn sues Illumina board over Grail acquisition
Activist Icahn sues Illumina board over Grail acquisition
Reuters
Illumina
Grail
M&A
Carl Icahn
Flag link:
EU to Order Illumina to Sell Grail After Years of Regulatory Challenges
EU to Order Illumina to Sell Grail After Years of Regulatory Challenges
BioSpace
Illumina
Grail
diagnostics
M&A
Europe
Flag link:
EU regulatory order for Illumina to sell Grail could come next week
EU regulatory order for Illumina to sell Grail could come next week
Reuters
Illumina
Grail
M&A
Europe
diagnostics
Medtech
Flag link:
SEC Investigating Illumina’s Multi-Billion Dollar Merger with GRAIL
SEC Investigating Illumina’s Multi-Billion Dollar Merger with GRAIL
BioSpace
SEC
Illumina
Grail
M&A
cancer
diagnostics
Flag link:
Grail sued by three female ex-employees over ‘toxic work culture’
Grail sued by three female ex-employees over ‘toxic work culture’
FT.com
Grail
diagnostics
legal
sexual harrassment
racial discrimination
Flag link:
Illumina hit by EU with maximum fine for Grail acquisition
Illumina hit by EU with maximum fine for Grail acquisition
BioPharma Dive
Illumina
Grail
M&A
Europe
Flag link:
As Illumina’s deSouza departs, will Grail go next?
As Illumina’s deSouza departs, will Grail go next?
BioPharma Dive
Illumina
Grail
Francis deSouza
M&A
Flag link:
Illumina Appeals FTC’s Ruling to Divest Grail
Illumina Appeals FTC’s Ruling to Divest Grail
Medical Devices and Diagnostics Industry
Illumina
FTC
Grail
M&A
Flag link:
Grail Expands Blood Test to Symptomatic Patients, Aims to Revolutionize Cancer Diagnosis
Grail Expands Blood Test to Symptomatic Patients, Aims to Revolutionize Cancer Diagnosis
BioSpace
Grail
diagnostics
Medtech
Galleri
cancer
Flag link:
Icahn pushes for spinoff of Illumina’s Grail division
Icahn pushes for spinoff of Illumina’s Grail division
BioPharma Dive
Illumina
Grail
Carl Icahn
M&A
spinoffs
Medtech
diagnostics
Flag link:
Why won’t Illumina sell Grail?
Why won’t Illumina sell Grail?
Medtech Dive
Illumina
M&A
Grail
Carl Icahn
Flag link:
FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail
FTC orders Illumina to divest $7.1 billion acquisition of cancer test developer Grail
CNBC
FTC
Illumina
Grail
competition
M&A
diagnostics
Flag link:
Illumina urges shareholders to reject Carl Icahn’s board nominees as proxy fight heats up
Illumina urges shareholders to reject Carl Icahn’s board nominees as proxy fight heats up
CNBC
Illumina
Carl Icahn
Grail
M&A
Flag link:
Illumina, facing Icahn challenge, ‘moving quickly’ on resolution for Grail
Illumina, facing Icahn challenge, ‘moving quickly’ on resolution for Grail
BioPharma Dive
Illumina
Grail
M&A
Medtech
diagnostics
Carl Icahn
Flag link:
Illumina Responds to Icahn Partners' Nomination of Directors
Illumina Responds to Icahn Partners' Nomination of Directors
BioSpace
Illumina
Carl Icahn
M&A
Grail
Flag link:
Carl Icahn takes proxy fight to Illumina: report
Carl Icahn takes proxy fight to Illumina: report
Endpoints
Illumina
Grail
M&A
Carl Icahn
Flag link:
Illumina Could Face Hefty Fine Over Grail Acquisition
Illumina Could Face Hefty Fine Over Grail Acquisition
Medical Devices and Diagnostics Industry
Illumina
Grail
M&A
antitrust
Europe
diagnostics
Medtech
Flag link:
Illumina loses its grip: the sequencing giant’s acquisition of Grail is heading for the rocks
Illumina loses its grip: the sequencing giant’s acquisition of Grail is heading for the rocks
EP Vantage
Illumina
M&A
Grail
Flag link:
Esmo 2022 – Galleri’s real-world exhibition disappoints
Esmo 2022 – Galleri’s real-world exhibition disappoints
EP Vantage
ESMO
Grail
Illumina
diagnostics
multi-cancer test
Galleri
Flag link:
Illumina’s hold on Grail depends now on separate appeals in US, Europe
Illumina’s hold on Grail depends now on separate appeals in US, Europe
BioSpace
Illumina
Grail
M&A
Europe
Flag link:

Pages